REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS-A COMPARATIVE ANALYSIS

被引：0
|
作者：
Hammerman, A. [1 ]
Klang, S. H. [1 ]
Liebermann, N. [1 ]
机构：
[1] Clalit Hlth Serv, Tel Aviv, Israel
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74272-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [41] Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
    Deng, Huan
    Liu, Wenfeng
    He, Ting
    Hong, Zhengdong
    Yi, Fengming
    Wei, Yiping
    Zhang, Wenxiong
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [42] Patterns of care in renal cell carcinoma: Comparison of treatment duration for first-line sunitinib and pazopanib
    Garofalo, David
    Montgomery, Jim
    Drenning, Jason
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
    Pill, Roberto
    Pal, Sumanta Kumar
    George, Saby
    Voortman, Jens
    Danchalvijitr, Pongwut
    Adelalye, Remi
    Webb, Nancy
    Poslinski, Diane
    Groman, Adrienne
    Hutson, Alan
    Verheul, Honk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Risk of treatment failure after first-line sunitinib therapy in patients with metastatic renal cell carcinoma.
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Hill, Jerrold W.
    Guo, Min Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [45] Sunitinib in the treatment of metastatic renal cell carcinoma
    Schmid, Thomas A.
    Gore, Martin E.
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (06) : 348 - 371
  • [46] Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma
    Herrmann, E.
    Marschner, N.
    Grimm, M. O.
    Ohlmann, C. H.
    Hutzschenreuter, U.
    Overkamp, F.
    Groschek, M.
    Blumenstengel, K.
    Puehse, G.
    Steiner, T.
    WORLD JOURNAL OF UROLOGY, 2011, 29 (03) : 361 - 366
  • [47] Sunitinib for the treatment of metastatic renal cell carcinoma
    Oudard, Stephane
    Beuselinck, Benoit
    Decoene, Jasper
    Albers, Peter
    CANCER TREATMENT REVIEWS, 2011, 37 (03) : 178 - 184
  • [48] Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    Choueiri, Toni K.
    Plantade, Anne
    Elson, Paul
    Negrier, Sylvie
    Ravaud, Alain
    Oudard, Stephane
    Zhou, Ming
    Rini, Brian I.
    Bukowski, Ronald M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 127 - 131
  • [49] Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry
    Boegemann, Martin
    Hubbe, Marcus
    Thomaidou, Despina
    Blackburn, Stuart
    Bent-Ennakhil, Nawal
    Wood, Robert
    Bargo, Danielle
    ANTICANCER RESEARCH, 2018, 38 (11) : 6413 - 6422
  • [50] Real world outcomes in metastatic renal cell carcinoma patients treated with sunitinib or pazopanib as first line therapy in the United States
    Smith, Tim
    Maclean, Elizabeth
    Mardekian, Jack
    Abernethy, Amy
    Harnett, James
    Clair, Andrew
    BJU INTERNATIONAL, 2016, 118 : 26 - 27
12345